Crossmark

Summary of Research: Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan

Crossref DOI link: https://doi.org/10.1007/s12325-024-02961-3

Published Online: 2024-09-19

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tangri, Navdeep

Rastogi, Anjay

Sofue, Tadashi
Funding

Funding for this research was provided by:

AstraZeneca
License Information

Text and Data Mining valid from 2024-09-19

Version of Record valid from 2024-09-19
More Information

Article History

Received: 29 May 2024

Accepted: 31 July 2024

First Online: 19 September 2024

Declarations

:

: Please see original article for full author disclosures.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Please see the referenced article for ethics relating to the original study.

Document is current

Any future updates will be listed below